CD Capital
CD Capital is a Shanghai-based MedTech-focused venture capital firm founded in 2013, managing over $1.4 billion across USD and RMB funds and backing more than 90 medical technology and life sciences companies worldwide.
- Company typePrivate
- Founded2013
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CD Capital does
CD Capital is a Shanghai-based venture capital firm founded in 2013 that specializes exclusively in medical technology and life sciences investments. The firm operates as a fund manager running parallel USD and RMB vehicles, with cumulative assets under management of over $1.4 billion. Since inception, it has backed more than 90 portfolio companies spanning medical devices, diagnostics, dental, surgical robotics, genomics, gene editing, and radiopharmaceuticals; notable holdings and exits include Urotronic (acquired by Laborie Medical Technologies for up to $600 million), Jenscare (HKEX: 9877), BMC Medical (ChiNext: 301367), Aidite (ChiNext: 301580), SprintRay, iRay Technology, Surgerii Robotics, Berry Genomics, KingMed Diagnostics, MicroTech Medical, HuidaGene, Full-Life Technologies, and Qi Biodesign.
The firm's investment methodology is described as a "win-win" model combining disciplined deal selection with a "precise, pragmatic post-investment empowerment system." CD Capital generates revenue through standard private-asset management streams: recurring management fees on committed and invested capital from institutional limited partners, plus performance-based carried interest realized at exit events. Portfolio liquidity has been demonstrated across multiple channels, including U.S. strategic acquisitions (Urotronic), Hong Kong IPO (Jenscare), and ChiNext listings (BMC Medical, Aidite), as well as continued growth-capital participation (SprintRay Series D, Full-Life Series B, Qi Biodesign Series A).
The firm is led by Founding Partner Ching Tan (ex-GE Healthcare China, Siguler Guff, Asia Tech VC, Booz & Company; Johns Hopkins M.S.E. in Biomedical Engineering, Chicago MBA), supported by Partners Larissa Lin (ex-UL China, J&J Medical, GE Healthcare) and Tianji Zhu (ex-Accenture). Operating geographies span Asia, North America, and Europe, with deal sourcing through an annual industry forum, professional networks, and direct submissions. The firm operates from a single Shanghai headquarters at Room 3906, 1168 West Nanjing Road.
CD Capital firmographics
Firmographics- Name
- CD Capital
- Legal name
- CD Capital (CDBI Partners)
- Website
- https://cd-healthinv.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CD Capital is a Shanghai-based MedTech-focused venture capital firm founded in 2013, managing over $1.4 billion across USD and RMB funds and backing more than 90 medical technology and life sciences companies worldwide.
- Ownership category
- akta.pro rank
CD Capital industry classification
Industry- Product category
- Venture Capital / Healthcare Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Venture Capital (CVC) (FSANAAAF)
Keywords
Where CD Capital is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
CD Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Revenue model
- Fund Management Fees: CD Capital manages over $1.4 billion across both USD funds and RMB funds, generating revenue through management fees from institutional investors.
- Carry/Performance Fees: As a venture capital firm, CD Capital generates returns through carry on successful exits of portfolio companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
CD Capital product offering
Product offeringCore offering
CD Capital is a Shanghai-based venture capital firm founded in 2013 that manages over $1.4 billion across USD and RMB funds. The firm invests in early- and growth-stage medical technology and life science companies, providing capital and post-investment empowerment to portfolio companies while generating returns through management fees and carried interest.
Product overview
CD Capital is a MedTech-focused venture capital firm, not a product/technology company. It does not offer a unified platform or product suite. The 'products_and_services' here refers to its core investment fund management services, which include managing healthcare-focused venture capital funds with capital deployment across portfolio companies in medical technology and biotechnology sectors. The firm has backed over 90 companies including Urotronic, iRay Technology, BMC Medical, SprintRay Inc, Surgerii Robotics, Berry Genomics, KingMed Diagnostics, Aidite, MicroTech Medical, Illumax, HuidaGene, Molbreeding, Qi-Biodesign, Full-Life, and Ibiome Biology.
Differentiator
Problem solved
Functional benefit
Products and services
- CD Capital Healthcare Investment Fund
Quantifiable outcome
- More than 90 portfolio investments backed since 2013
- +4 more outcomes
Companies that use CD Capital
Customer profileNamed customers16 records
Segments2 records
Ideal customer profiles2 records
CD Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CD Capital partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Laborie Medical TechnologiescoreAcquired Urotronic, a portfolio company of CD Capital, for up to $600 million (including $255 million upfront cash payment and up to $345 million in potential commercial and reimbursement milestone payments). CD Capital had been a long-term investor and director of Urotronic since 2015.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
CD Capital competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
CD Capital social profiles
Digital presenceCD Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
CD Capital leadership team
Management profileNumber of profiles
Profiles3 records
CD Capital funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CD Capital M&A and investment
M&A and investmentM&A
Investments66 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CD Capital
What does CD Capital do?
CD Capital is a Shanghai-based venture capital firm founded in 2013 that manages over $1.4 billion across USD and RMB funds. The firm invests in early- and growth-stage medical technology and life science companies, providing capital and post-investment empowerment to portfolio companies while generating returns through management fees and carried interest.
Is CD Capital a public or private company?
CD Capital is a private company. It is classified as unknown and is currently operating.
When was CD Capital founded?
CD Capital was founded in 2013. It employs 11 to 50 people.
Where is CD Capital based?
CD Capital is headquartered in Shanghai, China, in the Asia region.
How does CD Capital make money?
Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carry/Performance Fees.
Does CD Capital have an API?
No public API is recorded for CD Capital.
What industry is CD Capital in?
CD Capital's product category is Venture Capital / Healthcare Investment Management. Its primary akta.pro industry code is FSANAAAF, Corporate Venture Capital (CVC). Its NAICS code is 523940 and its SIC code is 6282.